| Identification | Back Directory | [Name]
(S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq | [CAS]
897369-18-5 | [Synonyms]
BCR-ABL-IN-2
BCR ABL IN 2,BCRABLIN2
(S)-6-(3-(tert-Butyl)-5-(3-(2,3-dichlorophenyl)ureido)-1H-pyrazol-1-yl)-1,2,3,4-tetrahydroisoq
3-Isoquinolinecarboxylic acid, 6-[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-1,2,3,4-tetrahydro-, (3S)- | [Molecular Formula]
C24H25Cl2N5O3 | [MDL Number]
MFCD28004774 | [MOL File]
897369-18-5.mol | [Molecular Weight]
502.39 |
| Hazard Information | Back Directory | [Uses]
BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. | [Definition]
ChEBI: DP-987 is a member of the class of phenylureas that is urea in which one of the nitrogens bears a 3-tert-butyl-1-[(3S)-3-carboxy-1,2,3,4-tetrahydroisoquinolin-6-yl]-1H-pyrazol-5-yl substituent, while the other bears a 2,3-dichlorophenyl group. It is a member of pyrazoles, a member of isoquinolines, a non-proteinogenic L-alpha-amino acid, a dichlorobenzene and a member of phenylureas. | [storage]
Store at -20°C | [References]
[1] Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011 Apr 12;19(4):556-68. DOI:10.1016/j.ccr.2011.03.003
[2] ARYL SULFONOHYDRAZIDES. US 2008/0113967 A1. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Matrix Scientific
|
| Tel: |
803 788-9494 All other calls |
| Website: |
www.matrixscientific.com |
|